Author:
Koroleva Elena V.,Ermolinskaya Anastasiya L.,Ignatovich Zhanna V.,Kornoushenko Yury V.,Panibrat Alesia V.,Potkin Vladimir I.,Andrianov Alexander M.
Reference55 articles.
1. Lugo, T. G., Pendergast, A. M., Muller, A. J., and Witte, O. N. (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products, Science, 247, 1079-1082,
https://doi.org/10.1126/science.2408149.
2. Deininger, M. W., Vieira, S., Mendiola, R., Schultheis, B., Goldman, J. M., and Melo, J. V. (2000) BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia, Cancer Res., 60, 2049-2055.
3. Quintás-Cardama, A., and Cortes, J. (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia, Blood, 113, 1619-1630,
https://doi.org/10.1182/blood-2008-03-144790.
4. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., and Talpaz, M. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome, N. Eng. J. Med., 344, 1038-1042,
https://doi.org/10.1056/NEJM200104053441402.
5. Ottmann, O. G., and Wassmann, B. (2002) Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts, Best Pract. Res. Clin. Haematol., 15, 757-769,
https://doi.org/10.1053/beha.2002.0233.